Esterase-responsive and Size-Optimized Prodrug Nanoparticles for Effective Intracranial Drug Delivery and Glioblastoma Treatment.

Zhang Ye,Lun Gao,Jiayang Cai,Yixuan Wang,Yong Li,Shiao Tong,Tengfeng Yan,Qian Sun,Yangzhi Qi,Yang Xu,Hongxiang Jiang,Si Zhang,Linyao Zhao,Shenqi Zhang,Qianxue Chen

DOI: https://doi.org/10.1016/j.nano.2022.102581

2022-01-01

SSRN Electronic Journal

Abstract:Glioblastoma multiforme (GBM) is the intracranial malignancy with the highest rates of morbidity and mortality. Chemotherapy is often ineffective against GBM due to the presence of the blood-brain barrier (BBB); however, the application of nanotechnology is expected to overcome this limitation. Poly(lactic-co-glycolic acid) (PLGA) is a degradable and nontoxic functional polymer with good biocompatibility that is widely used in the pharmaceutical industry. Previous studies have shown that the ability of PLGA nanoparticles (NPs) to penetrate the BBB is largely determined by their size; however, determination of the optimal PLGA NP size requires further research. Here, we report a tandutinib-based prodrug (proTan), which responds to the GBM microenvironment, that was combined with NPs to overcome the BBB. AMD3100-PLGA NPs loaded with proTan inhibited tumor growth and effectively prolonged the survival of tumor-bearing mice.